#chronic myeloid leukemia #CML #Delayed #ENACT #front-line #imatinib #Lebanon #nilotinib #poor response #resistant #second-line

Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon

by Dr. Fadi Farhat 0

Zaher K Otrock, Rami A Mahfouz, Zahera Fahed, Fadi S Farhat, Azzam Ziade, Fadi Nasr, Nader Kassem, Miguel R Abboud

PMID: 22961257

DOI: 10.1007/s12185-012-1168-9

No abstract available